Searchable abstracts of presentations at key conferences in endocrinology

ea0016oc4.4 | Bone and adrenal | ECE2008

Comparison of different test systems for the screening of inhibitors of CYP11B enzymes

Stuermer Andrea , Hahner Stafanie , Lang Katharina , Linss Heidi , Zink Martina , Schirbel Andreas , Allolio Bruno

Subject: Inhibitors of CYP11B enzymes, particularly of aldosterone synthase, are currently under development as adrenostatic agents in heart failure or hyperaldosteronism, and for use in adrenal imaging. As CYP11B1 and CYP11B2 show high homology, analysis of specific binding to the respective human enzymes is of key importance.Methods: Y1 cell lines stably expressing hsCYP11B1 or hsCYP11B2 were established. Primary cultures of porcine and human adrenocor...

ea0014oc3.5 | Endocrine tumors & neoplasia | ECE2007

[123I]Iodometomidate as a radiotracer for adrenal scintigraphy – first clinical experience

Hahner Stefanie , Stuermer Andrea , Fassnacht Martin , Kreissl Michael , Reiners Christoph , Beuschlein Felix , Zink Martina , Zolle Ilse , Schirbel Andreas , Allolio Bruno

Adrenal masses are highly prevalent tumours comprising of a variety of entities. Therefore, therapeutic consequences also vary considerably. The CYP11B-specific PET-tracer [11C]metomidate has been shown to be suitable to characterize adrenal lesions. However, its availability is restricted to PET-centers with an on-site cyclotron. Also imaging is hindered by the short tracer half-life (20 min). Therefore, we have developed [123I]iodometomidate as a tracer...

ea0022p23 | Adrenal | ECE2010

Sunitinib decreases adrenocortical cancer cell proliferation and specifically inhibits adrenal steroidogenesis

Reuss Miriam , Kroiss Matthias , Johanssen Sarah , Beyer Melanie , Zink Martina , Hartmann Michaela , Dhir Vivek , Wudy Stefan , Arlt Wiebke , Sbiera Silviu , Allolio Bruno , Fassnacht Martin

Background: The multi-tyrosine kinase inhibitor sunitinib is approved for advanced renal cell carcinoma and gastrointestinal stroma tumors. It targets both tumor vessels and malignant cells. Animal experiments have pointed to a direct adrenotoxic effect of the drug.Aims: We hypothesized that sunitinib may inhibit proliferation of adrenocortical cancer (ACC) cells and influence adrenal steroid hormone synthesis.Results: Sunitinib re...